Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Recarbrio

- PMLiVE

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

- PMLiVE

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

- PMLiVE

Merck’s Keytruda improves outcomes for metastatic cervical cancer patients

Keytruda improved overall survival and progression-free survival regardless of patients' PD-L1 status

- PMLiVE

The AMR Action Fund is combating antimicrobial resistance, but much more action is needed

By Henry Skinner, Chief Executive Officer of the AMR Action Fund

- PMLiVE

Merck & Co spinoff Organon launches with the aim of ‘improving health outcomes for women’

Merck & Co – known as MSD outside the US and Canada – announced its plans for the women’s health spinoff company last month

- PMLiVE

New trial data for Keytruda in triple-negative breast cancer

Keytruda plus chemotherapy showed significant and meaningful improvement

- PMLiVE

Merck & Co reveals plans for women’s health spinoff Organon

Company is expecting tax-free dividend of $9bn following close of spinoff

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Merck & Co to help produce J&J’s COVID-19 vaccine in the US

Company has signed agreements to bolster vaccine manufacturing capacity

- PMLiVE

MSD withdraws Keytruda’s US indication for small cell lung cancer

Checkpoint inhibitor gained accelerated approval in 2019

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

- PMLiVE

AMR Action Fund raises $140m from new investors to tackle antimicrobial resistance

New investment adds to initial $1bn raised at the Fund's launch last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links